Steven Gannon
Director · Xenon Pharmaceuticals Inc.
IndividualSelling only
- 2026
- Aug 13, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Steven Gannon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ian Mortimer - $21.42M in XENE purchases and sales in the last 12 months
- Christopher John Kenney - $670K in XENE purchases and sales in the last 12 months
- Thomas Patrick Kelly - $560K in XENE purchases and sales in the last 12 months
- Andrea Difabio - $231K in XENE purchases and sales in the last 12 months
- Gary Patou - $70K in XENE purchases and sales in the last 12 months
- Gillian Cannon - $63K in XENE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Steven Gannon?
Steven Gannon is a corporate insider, tracked as Director of Xenon Pharmaceuticals Inc. (XENE). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Steven Gannon submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Steven Gannon been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($641K) across all tracked filings.
